⭐ BioNTech SE and Bristol Myers Squibb entered into a global strategic partnership with a 50/50 profit/loss split to co-develop and co-commercialize BNT327 (PD-L1xVEGF-A BsAb) across numerous solid tumor types (Ref 1). ⭐ BMS will pay BioNTech $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary payments through 2028. ⭐ In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial mile